株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

薬物依存症:パイプライン製品の分析

Drug Addiction - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 251560
出版日 ページ情報 英文 162 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.37円で換算しております。
Back to Top
薬物依存症:パイプライン製品の分析 Drug Addiction - Pipeline Review, H2 2017
出版日: 2017年07月25日 ページ情報: 英文 162 Pages
概要

薬物依存症は物質依存症とも呼ばれており、破壊的パターンに至った場合には、その物質への耐性や依存脱却に多大な困難が伴うようになります。薬物依存症患者の主な症状・行動として、薬物の頻繁な利用により、職場・学校・家庭でなすべき必要な行動が取れなくなる、不眠症、睡眠リズムの不規則化、異常な怠惰感、拒食症/過食症、食事行動の変化、手のひらの体温低下・発汗、手の振るえ、目の充血・涙目、瞳孔拡張/縮小、呼吸・人体・服から異臭がする、などが挙げられます。

当レポートでは、世界各国での薬物依存症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

薬物依存症の概要

治療薬の開発

  • 薬物依存症向けパイプライン製品:概要
  • 薬物依存症向けパイプライン製品:比較分析

各企業で開発中の薬物依存症治療薬

大学/研究機関で研究中の薬物依存症治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品
  • 不明確な段階にある製品

薬物依存症治療薬:開発中の製品の一覧(企業別)

薬物依存症治療薬:研究中の製品の一覧(大学/研究機関別)

薬物依存症治療薬の開発に従事している企業

  • Gilead Sciences, Inc.
  • Aphios Corporation
  • Teva Pharmaceutical Industries Limited
  • Addex Therapeutics Ltd.
  • Biotie Therapies Corp.
  • Camurus AB
  • Curemark, LLC
  • Rottapharm SpA
  • Omeros Corporation
  • Immunovaccine, Inc.
  • 杏林製薬
  • D&A Pharma SAS
  • Embera NeuroTherapeutics, Inc.
  • Lightlake Therapeutics Inc.
  • SK Biopharmaceuticals Co., Ltd.
  • LondonPharma Ltd.

薬物依存症:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • 塩酸ネピカスタット
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • イブジラスト
  • 塩酸ブプレノルフィン
  • TV-1380
  • カンナビジオール
  • オキサゼパム+メチラポン
  • SKL-N05
  • LT-22
  • ASB
  • メタドン
  • GS-6673
  • ドロナビノール
  • ADX-88178
  • ADX-71441
  • OMS-527
  • コカイン中毒向けワクチン
  • コカイン中毒向けワクチン
  • MH-6ワクチン
  • 薬物依存症向けワクチン
  • イボガインのアナログ(類似体)
  • コカイン中毒・コカイン乱用向けDAT阻害用小分子
  • 中枢神経系(CNS)疾患・代謝障害向け5HT2修飾用小分子
  • CM-1212
  • methoxycoronaridine
  • がん・コカイン依存症向けBRD阻害用小分子
  • CR-5542シリーズ
  • 中枢神経系(CNS)疾患向けDAT・SERT阻害用小分子
  • 免疫疾患・中枢神経系(CNS)疾患・代謝障害向けδオピオイド受容体活性化用小分子
  • カンナビノイド乱用・薬物依存症向けCB1受容体阻害用小分子
  • 中枢神経系(CNS)疾患向けκオピオイド受容体活性化用小分子
  • 中枢神経系(CNS)疾患向けκオピオイド受容体阻害用小分子
  • 依存症向け医薬品

薬物依存症治療薬:パイプライン製品の最新動向

薬物依存症治療薬:開発が休止状態の製品

薬物依存症治療薬:開発が中止された製品

薬物依存症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全10件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9580IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H2 2017, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 7, 7, 1, 29, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 5 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Drug Addiction - Overview
    • Drug Addiction - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
  • Products under Development by Universities/Institutes
    • Drug Addiction - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Addiction - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Aelis Farma SAS
    • Aphios Corp
    • BioCorRx Inc
    • Cerecor Inc
    • Chiesi Farmaceutici SpA
    • Curemark LLC
    • Egalet Corp
    • Embera NeuroTherapeutics Inc
    • F. Hoffmann-La Roche Ltd
    • Foresee Pharmaceuticals LLC
    • Heptares Therapeutics Ltd
    • Immunovaccine Inc
    • Indivior Plc
    • InterveXion Therapeutics LLC
    • Intra-Cellular Therapies Inc
    • Kyorin Pharmaceutical Co Ltd
    • Kyowa Hakko Kirin Co Ltd
    • Omeros Corp
    • Opiant Pharmaceuticals Inc
    • Orexigen Therapeutics Inc
    • P2D Bioscience
    • Saniona AB
    • Stada Arzneimittel AG
    • Teva Pharmaceutical Industries Ltd
    • Zynerba Pharmaceuticals Inc
  • Drug Addiction - Drug Profiles
    • (acetaminophen + hydrocodone bitartrate + Respiratory Drug) - Drug Profile
    • (hydrocodone bitartrate + naltrexone hydrochloride) - Drug Profile
    • (metyrapone + oxazepam) - Drug Profile
    • 18-MC - Drug Profile
    • ADX-71441 - Drug Profile
    • ADX-71743 - Drug Profile
    • ADX-88178 - Drug Profile
    • AEF-0117 - Drug Profile
    • ANS-6637 - Drug Profile
    • AT-076 - Drug Profile
    • AT-089 - Drug Profile
    • AT-1001 - Drug Profile
    • AT-212 - Drug Profile
    • Biologic to Agonize TLR4 for Drug Addiction - Drug Profile
    • cannabidiol - Drug Profile
    • CERC-501 - Drug Profile
    • CM-1212 - Drug Profile
    • DDD-024 - Drug Profile
    • dronabinol - Drug Profile
    • dronabinol - Drug Profile
    • Drug for Addiction - Drug Profile
    • Enzyme for Cocaine Addiction - Drug Profile
    • EORA-101 - Drug Profile
    • EP-11313 - Drug Profile
    • FP-004 - Drug Profile
    • Gene Therapy to Activate Cocaine Hydrolase for Cocaine Abuse - Drug Profile
    • h-2E2 - Drug Profile
    • ibudilast - Drug Profile
    • istradefylline - Drug Profile
    • ITI-333 - Drug Profile
    • IXT-m200 - Drug Profile
    • JDTic - Drug Profile
    • JQ-1 - Drug Profile
    • KDAC-0001 - Drug Profile
    • levofacetoperane - Drug Profile
    • lofexidine hydrochloride - Drug Profile
    • MC-100093 - Drug Profile
    • naltrexone hydrochloride SR - Drug Profile
    • NLS-10 - Drug Profile
    • NS-2359 - Drug Profile
    • OMS-405 - Drug Profile
    • OMS-527 - Drug Profile
    • OPNT-001 - Drug Profile
    • OREX-1019 - Drug Profile
    • OREX-1038 - Drug Profile
    • oxycodone hydrochloride - Drug Profile
    • RBP-8000 - Drug Profile
    • Recombinant Enzyme for Cocaine Abuse - Drug Profile
    • RO-5256390 - Drug Profile
    • SERx-480 - Drug Profile
    • Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile
    • Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
    • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
    • Small Molecules for Neonatal Abstinence Syndrome - Drug Profile
    • Small Molecules to Block VMAT2 for Methamphetamine Addiction - Drug Profile
    • Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile
    • Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
    • Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
    • Small Molecules to Inhibit Kappa Opioid Receptor for CNS - Drug Profile
    • Small Molecules to Scavenge Free Radicals for Oxidative Stress Related Disorders - Drug Profile
    • Small Molecules to Target 5HT2 for CNS Disorders and Obesity - Drug Profile
    • Small Molecules to Target Nicotinic Acetylcholine Receptors for Drug Addiction and Drug Abuse - Drug Profile
    • Synthetic Peptide to Target Kappa Opioid Receptors for Drug Addiction - Drug Profile
    • Vaccine for Cocaine Addiction - Drug Profile
    • Vaccine for Drug Abuse - Drug Profile
    • Vaccine for Methamphetamine Abuse - Drug Profile
    • Vaccine for Methamphetamine Addiction - Drug Profile
    • VU-0463841 - Drug Profile
  • Drug Addiction - Dormant Projects
  • Drug Addiction - Discontinued Products
  • Drug Addiction - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Drug Addiction, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Drug Addiction - Pipeline by Addex Therapeutics Ltd, H2 2017
  • Drug Addiction - Pipeline by Aelis Farma SAS, H2 2017
  • Drug Addiction - Pipeline by Aphios Corp, H2 2017
  • Drug Addiction - Pipeline by BioCorRx Inc, H2 2017
  • Drug Addiction - Pipeline by Cerecor Inc, H2 2017
  • Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, H2 2017
  • Drug Addiction - Pipeline by Curemark LLC, H2 2017
  • Drug Addiction - Pipeline by Egalet Corp, H2 2017
  • Drug Addiction - Pipeline by Embera NeuroTherapeutics Inc, H2 2017
  • Drug Addiction - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Drug Addiction - Pipeline by Foresee Pharmaceuticals LLC, H2 2017
  • Drug Addiction - Pipeline by Heptares Therapeutics Ltd, H2 2017
  • Drug Addiction - Pipeline by Immunovaccine Inc, H2 2017
  • Drug Addiction - Pipeline by Indivior Plc, H2 2017
  • Drug Addiction - Pipeline by InterveXion Therapeutics LLC, H2 2017
  • Drug Addiction - Pipeline by Intra-Cellular Therapies Inc, H2 2017
  • Drug Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
  • Drug Addiction - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017
  • Drug Addiction - Pipeline by Omeros Corp, H2 2017
  • Drug Addiction - Pipeline by Opiant Pharmaceuticals Inc, H2 2017
  • Drug Addiction - Pipeline by Orexigen Therapeutics Inc, H2 2017
  • Drug Addiction - Pipeline by P2D Bioscience, H2 2017
  • Drug Addiction - Pipeline by Saniona AB, H2 2017
  • Drug Addiction - Pipeline by Stada Arzneimittel AG, H2 2017
  • Drug Addiction - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
  • Drug Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2017
  • Drug Addiction - Dormant Projects, H2 2017
  • Drug Addiction - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Drug Addiction - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Drug Addiction - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Drug Addiction, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top